Matrix catabolism in arthritis: Priming the guns with oncostatin M

Journal of Rheumatology

Volumn 31, Issue 12, 2004, Pages 2326-2328

  Richards, Carl D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE; CELL ADHESION MOLECULE; CHEMOKINE; COLLAGENASE 3; ICOSANOID; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 23; INTERSTITIAL COLLAGENASE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOSTATIN M; OSTEOCLAST DIFFERENTIATION FACTOR; STEROID; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

B LYMPHOCYTE; CATABOLISM; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; EXTRACELLULAR MATRIX; HUMAN; INFECTION; INFLAMMATORY CELL; MACROPHAGE; NONHUMAN; OSTEOARTHRITIS; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIUM; T LYMPHOCYTE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; MICE; ONCOSTATIN M; PEPTIDES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10044240654     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (27)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 2002;4:157-64.
3. Mengshol JA, Mix KS, Brinckerhoff CE. Matrix metalloproteinases as therapeutic targets in arthritic diseases. Arthritis Rheum 2002;46:13-20.
4. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-27.
5. Malemud CJ, Islam N, Haqqi TM. Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs 2003;174:34-48.
6. Pelletier J-P, Martel-Pelletier J. Oncostatin M: foe or friend? Arthritis Rheum 2003;48:3301-3.
7. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
8. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
9. Van den Berg WB. Is there a rationale for combined TNF and IL-1 blocking in arthritis? Clin Exp Rheumatol 2002;20 Suppl 27:521-5.
10. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
11. McInnes IB, Gracie JA, Harnett M, Harnett W, Liew FY. New strategies to control inflammatory synovitis: interleukin 15 and beyond. Ann Rheum Dis 2003;62 Suppl II:ii51-ii54.
12. Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-9.
13. Liew FY, Wei X-Q, McInnes IB. Role of interleukin 18 in rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl II:ii48-ii50.
14. Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7.
15. Wong PKK, Campbell IK, Egan PJ, Ernst M, Wicks IP. The role of interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum 2003;48:1177-89.
16. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46:3143-50.
17. Langdon C, Leith J, Smith F, Richards CD. Oncostatin M stimulates monocyte chemoattractant protein-1 and interleukin-1-induced matrix metalloproteinase-1 production by human synovial fibroblasts in vitro. Arthritis Rheum 1997;40:2139-46.
18. Rowan AD, Koshy PJ, Shingleton WD, et al. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum 2001;44:1620-32.
19. Koshy PJT, Lundy CJ, Rowan AD, et al. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M. Arthritis Rheum 2002;46:961-7.
20. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002;61:704-13.
21. Li WQ, Dehnade F, Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 2001;166:3491-8.
22. Langdon C, Kerr C, Hassen M, Hara T, Arsenault AL, Richards CD. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol 2000;157:1187-96.
23. de Hooge ASK, van de Loo FAJ, Bennink M, et al. Growth plate damage, a feature of juvenile idiopathic arthritis, can be induced by adenoviral gene transfer of oncostatin M. Arthritis Rheum 2003;48:1750-61.
24. Rowan AD, Hui W, Cawston TE, Richards CD. Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model. Am J Pathol 2003;162:1975-84.
25. Hui W, Rowan AD, Richards CD, Cawston TE. Oncostatin M in combination with tumour necrosis factor induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum 2003;48:3404-18.
26. Plater-Zyberk C, Buckton J, Thompson S, et al. Amelioration of arthritis in two murine models using antibodies to oncostatin M. Arthritis Rheum 2001;44:2697-702.
27. Tanaka M, Hirabayashi Y, Sekiguchi T, Inoue T, Katsuki M, Miyajima A. Targeted disruption of oncostatin M receptor results in altered hematopoiesis. Blood 2003;102:3154-62.